Physician profile
Austin Lively
NPI 1871976639
$648.12
in general payments reported to CMS, 2019-2025
12 companies · $34.62 in 2025
The $34.62 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.20 · 2020: $104 · 2021: $79.32 · 2022: $191 · 2023: $47.12 · 2024: $98.76 · 2025: $34.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $180.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $238.23 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $110.63 | 2019-2024 | M-M-R II, Vaxelis, Vaxneuvance |
| Pfizer INC. | $83.61 | 2019-2024 | |
| Sanofi Pasteur INC. | $47.50 | 2022-2025 | |
| Adlon Therapeutics L.P. | $37.98 | 2021 | |
| Qol Medical, LLC | $32.20 | 2022 | |
| Ironshore Pharmaceuticals INC. | $21.06 | 2019 | |
| Genentech USA, INC. | $19.75 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $17.44 | 2024 | Flumist Quadrivalent |
| Phadia US INC. | $15.75 | 2019 | |
| Glaxosmithkline, LLC. | $12.06 | 2019 | |
| Neurelis, INC. | $11.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Lively listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.